Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: The aim of this study was to investigate the impact of statin and metformin therapy on disease outcome for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: This retrospective study included 171 PDAC patients who underwent surgical resection at the Stanford Cancer Institute between 1998 and 2013. No patients received neoadjuvant therapy. Statin and metformin use was defined as use during initial consult and continuing upon discharge from the hospital after surgery. Dose of each medication was recorded, as was the type of statin taken. RESULTS: The median follow-up for all patients was 11.23 months (range, 0.2-105.0 months). Among the 171 patients included in our analysis, 18 patients (10.5%) took metformin and 34 patients (19.9%) took statins. Statin use was associated with better overall survival (OS) in patients with PDAC (P = 0.011). Metformin use was also associated with better OS (P = 0.035). The use of statins remained significant on multivariate analysis for OS (P = 0.014; hazards ratio, 0.33; 95% confidence interval, 0.139-0.799), but metformin use did not (P = 0.33; hazards ratio 0.60, 95% confidence interval, 0.211-1.675). CONCLUSIONS: Statin and metformin use is associated with improved OS in patients with resectable PDAC. These medications should be further investigated for possible long-term use in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Sahra, I. B., Laurent, K., Loubat, A., Giorgetti-Peraldi, S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-Brustel, Y., & Bost, F. (2008) · Oncogene · doi:10.1038/sj.onc.1211024 · Cited by 861 · cited 1×
“Preclinical data indicate that metformin is able to attenuate pancreatic cancer cell growth through the inhibition of the AMPK/mTOR pathway(15) and induction of cell cycle arrest.(16,17) To date, only 2 clinical studies have shown a relationship between metformin use and pancreatic cancer.”
BackgroundMetformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Ben Sahra, I., Le Marchand-Brustel, Y., Tanti, J.-F., & Bost, F. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1186 · Cited by 493 · cited 1×
“Metformin belongs to the biguanide class of oral hypoglycemic agents and is a widely used antidiabetic drug prescribed to nearly 120 million people worldwide.(14) Several in vitro and in vivo studies have shown that metformin prevents the progression of cancer by targeting the AMPK/mTOR pathway and inducing cell cycle…”
BackgroundStatin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Cited by
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis
Tamburrino, D., Crippa, S., Partelli, S., Archibugi, L., Arcidiacono, P. G., Falconi, M., & Capurso, G. (2020) · Digestive and Liver Disease · doi:10.1016/j.dld.2020.01.008 · Cited by 54
Shi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F. (2020) · Medicine · doi:10.1097/md.0000000000021687 · Cited by 43
Chen, Y., Huang, Y., Yang, S., Yen, H., Tsai, H., Hsieh, M., & Hsiao, Y. (2021) · Environmental Toxicology · doi:10.1002/tox.23146 · Cited by 26
Statin use after cancer diagnosis and survival among patients with cancer
Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2025) · Cancer Causes & Control · doi:10.1007/s10552-024-01939-4 · Cited by 4
Metadata
- Authors
- Kozak, M. M., Anderson, E. M., von Eyben, R., Pai, J. S., Poultsides, G. A., Visser, B. C., Norton, J. A., Koong, A. C., & Chang, D. T.
- Venue
- Pancreas
- Published
- 2016-01
- Volume
- 45
- Issue
- 1
- Pages
- 64-70
- ISSN
- 0885-3177 (ISSN-L)
- OpenAlex
- W2407087714
- Cited by
- 50
- References
- 7
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. https://app.cochat.ai/papers/10.1097/mpa.0000000000000470
- The paper
- Kozak, M. M., Anderson, E. M., von Eyben, R., Pai, J. S., Poultsides, G. A., Visser, B. C., Norton, J. A., Koong, A. C., & Chang, D. T. (2016). Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Pancreas. https://doi.org/10.1097/mpa.0000000000000470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.